Different Mismatch Concepts for Magnetic Resonance Imaging-Guided Thrombolysis in Unknown Onset Stroke.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
06 2020
Historique:
received: 13 11 2019
revised: 17 03 2020
accepted: 22 03 2020
pubmed: 1 4 2020
medline: 21 10 2020
entrez: 1 4 2020
Statut: ppublish

Résumé

To explore the prevalence of the perfusion-weighted imaging (PWI)-diffusion-weighted imaging (DWI) mismatch and response to intravenous thrombolysis in the WAKE-UP trial. We performed a prespecified post hoc analysis of ischemic stroke patients screened for DWI-fluid-attenuated inversion recovery (FLAIR) mismatch in WAKE-UP who underwent PWI. We defined PWI-DWI mismatch as ischemic core volume < 70ml, mismatch volume > 10ml, and mismatch ratio > 1.2. Primary efficacy end point was a modified Rankin Scale score of 0-1 at 90 days, adjusted for age and symptom severity. Of 1,362 magnetic resonance imaging-screened patients, 431 underwent PWI. Of these, 57 (13%) had a double mismatch, 151 (35%) only a DWI-FLAIR mismatch, and 54 (13%) only a PWI-DWI mismatch. DWI-FLAIR mismatch was more prevalent than PWI-DWI mismatch (48%, 95% confidence interval [CI] = 43-53% vs 26%, 95% CI = 22-30%; p < 0.0001). Screening for either one of the mismatch profiles resulted in a yield of 61% (95% CI = 56-65%). Prevalence of PWI-DWI mismatch was similar in patients with (27%) or without (24%) DWI-FLAIR mismatch (p = 0.52). In an exploratory analysis in the small subgroup of 208 randomized patients with PWI, PWI-DWI mismatch status did not modify the treatment response (p for interaction = 0.73). Evaluating both the DWI-FLAIR and PWI-DWI mismatch patterns in patients with unknown time of stroke onset will result in the highest yield of thrombolysis treatment. The treatment benefit of alteplase in patients with a DWI-FLAIR mismatch seems to be driven not merely by the presence of a PWI-DWI mismatch, although this analysis was underpowered. ANN NEUROL 2020;87:931-938.

Identifiants

pubmed: 32227638
doi: 10.1002/ana.25730
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

931-938

Informations de copyright

© 2020 American Neurological Association.

Références

Thomalla G, Cheng B, Ebinger M, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol 2011;10:978-986.
Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018;379:611-622.
Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019;380:1795-1803.
Fink JN, Kumar S, Horkan C, et al. The stroke patient who woke up: clinical and radiological features, including diffusion and perfusion MRI. Stroke 2002;33:988-993.
Mackey J, Kleindorfer D, Sucharew H, et al. Population-based study of wake-up strokes. Neurology 2011;76:1662-1667.
Horos. Our mission. Available at: https://horosproject.org/about/.
van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.
Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
Wouters A, Dupont P, Ringelstein EB, et al. Association between the perfusion/diffusion and diffusion/FLAIR mismatch: data from the AXIS2 trial. J Cereb Blood Flow Metab 2015;35:1681-1686.
Wouters A, Dupont P, Christensen S, et al. Association between time from stroke onset and fluid-attenuated inversion recovery lesion intensity is modified by status of collateral circulation. Stroke 2016;47:1018-1022.
Campbell BC, Christensen S, Tress BM, et al. Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab 2013;33:1168-1172.
Cheng B, Rosenkranz M, Krutzelmann A, et al. The extent of perfusion deficit does not relate to the visibility of acute ischemic lesions on fluid-attenuated inversion recovery imaging. J Neuroimaging 2013;23:215-218.
Berthezene Y, Eker O, Makris N, et al. Collateral circulation assessment within the 4.5h time window in patients with and without DWI/FLAIR MRI mismatch. J Neurol Sci 2018;394:94-98.
Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018;378:708-718.
Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018;378:11-21.

Auteurs

Lauranne Scheldeman (L)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Leuven, Belgium.
Center for Brain & Disease Research, Laboratory of Neurobiology, Flanders Institute for Biotechnology, Leuven, Belgium.

Anke Wouters (A)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Leuven, Belgium.
Center for Brain & Disease Research, Laboratory of Neurobiology, Flanders Institute for Biotechnology, Leuven, Belgium.

Florent Boutitie (F)

Hospices Civils de Lyon, Service de Biostatistique, F-69003 Lyon, France; Université Lyon 1, F-69100, Villeurbanne, France.
Centre national de la recherche scientifique, unité mixte de recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France.

Patrick Dupont (P)

Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven-University of Leuven, Leuven, Belgium.

Soren Christensen (S)

GrayNumber Analytics, Lomma, Sweden.

Bastian Cheng (B)

Department of Neurology, Head and Neurocenter, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Martin Ebinger (M)

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Neurology Clinic, Medical Park Berlin Humboldtmühle, Berlin, Germany.

Matthias Endres (M)

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
German Center for Cardiovascular Research, Berlin, Germany.
German Center for Neurodegenerative Diseases, Berlin, Germany.

Jochen B Fiebach (JB)

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Christian Gerloff (C)

Department of Neurology, Head and Neurocenter, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Keith W Muir (KW)

Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, United Kingdom.

Norbert Nighoghossian (N)

Department of Stroke Medicine, Claude Bernard University Lyon 1, CREATIS National Center for Scientific Research Mixed Unit of Research 5220-National Institute of Health and Medical Research U1206, National Institute of Applied Sciences of Lyon, Lyon Civil Hospices, Lyon, France.

Salvador Pedraza (S)

Department of Radiology, Institute of Diagnostic Imaging, Dr Josep Trueta Hospital, Girona Institute of Biomedical Research, Marti and Julia de Salt Hospital Park - Building M2, Girona, Spain.

Claus Z Simonsen (CZ)

Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.

Vincent Thijs (V)

Stroke Theme, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia.
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia.

Götz Thomalla (G)

Department of Neurology, Head and Neurocenter, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Robin Lemmens (R)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Department of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Leuven, Belgium.
Center for Brain & Disease Research, Laboratory of Neurobiology, Flanders Institute for Biotechnology, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH